38502-28-2

Usage

Uses

Used in Coatings Industry:
(1-methylcyclopentyl)methanol is used as a solvent for the production of coatings, aiding in the application process and improving the final product's quality.
Used in Adhesives Industry:
(1-methylcyclopentyl)methanol is used as a solvent in the production of adhesives, enhancing their bonding properties and performance.
Used in Cleaning Products Industry:
(1-methylcyclopentyl)methanol is used as a solvent in cleaning products, contributing to their effectiveness in removing dirt and stains.
Used as a Precursor in Organic Synthesis:
(1-methylcyclopentyl)methanol is used as a precursor in the synthesis of other organic compounds, including pharmaceuticals and fragrances, due to its reactive nature and ability to form a wide range of derivatives.
Safety Precautions:
It is important to handle (1-methylcyclopentyl)methanol with caution due to its moderate toxicity if ingested or inhaled, and its potential to cause skin and eye irritation. Adhering to proper safety procedures is essential when working with (1-methylcyclopentyl)methanol in an industrial setting.

Upstream product

• 67-56-1 methanol 
• 96-37-7 methyl-cyclopentane 
• 3400-45-1 cyclopentanecarboxylic acid 
• 108-93-0 cyclohexanol 
• 4630-80-2 methyl cyclopentane carboxylate 
• 175-57-5 2-oxa-spiro[3.4]octane 
• 4630-83-5 methyl 1-methylcyclopentanecarboxylate 
• 5217-05-0 1-methylcyclopentanecarboxylic acid 

Downstream Products

• 85002-79-5 1-(1-Methyl-cyclopentylmethoxy)-4-nitro-benzene 
• 1123-25-7 1-methyl-1-cyclohexanecarboxylic acid 
• 6140-63-2 1-methyl-1-cyclopentanecarbaldehyde 
• 1360568-99-5 (3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360568-98-4 (3R,4S,5S,6R)-2-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1360568-97-3 4-bromo-1-chloro-2-(4-((1-methylcyclopentyl)methoxy)benzyl)benzene 
• 1360569-38-5 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-37-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-methylcyclopentyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360568-96-2 (1-methylcyclopentyl)methyl 4-methylbenzenesulfonate 
• 1638-26-2 1,1-Dimethylcyclopentane 
• 85010-73-7 2-Imino-5-[4-(1-methyl-cyclopentylmethoxy)-benzyl]-thiazolidin-4-one 
• 74773-25-4 5-[4-(1-Methyl-cyclopentylmethoxy)-benzyl]-thiazolidine-2,4-dione 
• 85003-40-3 2-Chloro-3-[4-(1-methyl-cyclopentylmethoxy)-phenyl]-propionic acid methyl ester 
• 951789-90-5 C₁₆H₂₃NO₃ 

Relevant academic research and scientific papers

Organic electroluminescent material and device (by machine translation)

The invention relates to the organic electroluminescent material and device. Discloses a composition, comprising a compound 1st, the 1st compounds can be at room temperature acts as an organic light-emitting device in the phosphorescent emitter. The 1st c

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

3- (1H-PYRAZOL-4-YL) PYRIDINEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS

The invention relates to the cycloalkyl methoxybenzyl phenyl pyran derivatives as Sodium dependent glucose co transporter (SGLT) inhibitors, particularly SGLT2 and method of treating diseases, conditions and/or disorders inhibited by SGLT2 with them, and processes for preparing them.

Practical and efficient method for amino acid derivatives containing β-quaternary center: application toward synthesis of hepatitis C virus NS3 serine protease inhibitors

A practical and efficient route toward synthesis of amino acid derivatives containing β-quaternary center has been developed using diastereoselective Strecker reaction. The method was employed for preparation of >100 g of β-methylcyclohexyl glycine deriva

Cyclization by intramolecular carbolithiation of alkyl- and vinyllithiums prepared by the action of aromatic radical anions on phenyl thioethers. High stereoselectivity in the cyclization accelerated by an allylic lithium oxyanion

The reductive lithiation of alkyl and vinyl phenyl thioethers by aromatic radical anions is shown to be the most general method yet known for preparing organolithiums capable of intramolecular carbometalation of unactivated alkenes to produce five-membered rings and in one case a four-membered ring (in a far higher yield than known cases). The relative rates of cyclization for alkyllithiums are secondary > tertiary > primary, and the yields are very high. In the secondary case, the stereoselectivity is extremely high, producing a cyclopentylmethyllithium with a trans-2-alkyl substituent. A remarkable finding is that for all of the organolithiums a lithium oxyanionic group in the proximal allylic position to the alkene greatly accelerates the cyclization and leads almost exclusively to a trans relationship between the CH2Li group and the OLi group, the opposite relationship from that observed in intramolecular carbolithiations by allyllithiums. A mechanistic rationale for this divergence is discussed. One of the two types of proximal homoallylic lithium oxyanions exerts an analogous effect. An intriguing limitation, even occurring with the highly reactive secondary organolithium and in the presence of an allylic oxyanionic group, is the failure of intramolecular carbolithiation when a methyl group is at the terminus of the alkene.

Cyclization by intramolecular carbolithiation of alkyl- and vinyllithiums prepared by reductive lithiation: Surprising stereochemistry in the lithium oxyanion accelerated cyclization

The versatility of intramolecular carbolithiation of simple alkenes to yield cyclopentylmethyllithiums by unconjugated organolithiums is greatly increased (1) by generating the organolithiums by reductive lithiation of phenyl thioethers with aromatic radi

Alkane Functionalization on a Preparative Scale by Mercury-Photosensitized Cross-Dehydrodimerization

Alkanes can be functionalized with high conversions and in high chemical and quantum yields on a multigram scale by mercury-photosensitized reaction between an alkane and alcohols, ethers, or silanes to give homodimers and cross-dehydrodimers.The separation of the product mixtures is often particulary easy because of a great difference in polarity of the homodimers and cross-dimers.It is also possible to bias the product composition when the ratio of the components in the vapor phase is adjusted by altering the liquid composition.This is useful either to maximize chemical yield or to ease separation by favoring the formation of the most easily separated pair of compounds.The mechanistic basis of the reaction is discussed and a number of specific types of syntheses, for example of 2,2-disubstituted carbinols, are described in detail.The selectivity of cross-dimerization is shown to exceed that for homodimerization and reasons are discussed.Relative reactivities of different compounds and classes of compound are MeOHp-dioxanecyclohexane1,3,5-trioxacyclohexaneethanolisobutaneTHFEt3SiH.The observed selectivities generally parallel those for homodimerization, reported in the preceding paper, but certain differences are noted, and reasons for the differences are proposed.The bond-dissociation energy of Et3SiH is estimated from the reactivity data to be 90 kcal/mol.Eleven new carbinols are synthesized.

Deuterium Isotope Effects for Migrating and Nonmigrating Groups in the Solvolysis of Neopentyl-Type Esters

α- and γ-deuterium rate effects on the solvolysis of (1-methylcyclohexyl)methyl, (1-methylcyclopentyl)methyl, and (1-methylcyclobutyl)methyl sulfonate esters have been measured and the solvolysis products examined by 2H NMR spectroscopy.The results indicate that the products of the solvolysis of all these sulfonate esters are predominantely ((*) 98percent) rearranged.In the solvolysis of (1-methylcyclohexyl)methyl triflate, rearranged products with methyl migration slightly dominate over those with ring expansion.Normal isotope effects, 1.057 in 80E and 1.073 in 97T, are observed for the methyl-d3 compound and an inverse effect, 0,963, is observed in 80E for the methylene-d4 compound.However, in the solvolysis of both (1-methylcyclopentyl)methyl and (1-methylcyclobutyl)methyl sulfonates, the major products are those of ring expansion.In these examples, inverse effects are observed for the methyl-d3-labeled species.The observed isotope effects can be separated into respective values of 0.927, 0.913 for the nonmigrating methyl-d3 group and 1.177, 1.224 for the migrating methyl-d3 group in the solvolysis of (1-methylcyclohexyl)methyl triflate and (1-methylcyclopentyl)methyl brosylate.This explains the relative intramolecular migratory aptitudes of CH3/CD3 of 1.20 - 1.30 and the low γ-d9 isotope effect in the solvolysis of neopentyl sulfonates previously reported and makes them consistent with a mechanism which involves neighboring carbon participation during ionization.

Preparation of 15-deoxy-16-hydroxyprostaglandins

Analogues of PGE1 having the structural formula, STR1 in which J is R-hydroxymethylene or S-hydroxymethylene; R1 is hydrogen; R2 is hydrogen or together with R4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R3 is hydrogen or methyl, or together with R4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R4 is bicycloalkyl or bicycloalkenyl moiety having the formula: STR2 SUCH THAT A BICYCLOALKYL OR BICYCLOALKENYL COMPOUND IS FORMED, WHEREIN M AND N ARE INTEGERS HAVING A VALUE FROM 0 TO 3, P IS AN INTEGER HAVING A VALUE FROM 0 TO 4 AND Q IS AN INTEGER HAVING A VALUE OF FROM 1 TO 4 AND WHEREIN THE DOUBLE BOND OF SUCH BICYCLOALKENYL IS IN THE M, N, P, OR Q BRIDGE; R4 is hydrogen or methyl or together with R2 or R3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R4 forms a cycloalkyl as defined above; and R6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. Pge1 ester analogues of the above formula, limited to the structures wherein two of R2, R3 R4 and R5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.